| Literature DB >> 32582344 |
Zeinab Iraji1, Tohid Jafari Koshki1, Roya Dolatkhah2, Mohammad Asghari Jafarabadi1,3.
Abstract
BACKGROUND: Breast cancer (BC) was the fifth cause of mortality worldwide in 2015 and second cause of mortality in Iran in 2012. This study aimed to explore factors associated with survival of patients with BC using parametric survival models.Entities:
Keywords: Accelerated failure time; breast cancer; parametric model; survival
Year: 2020 PMID: 32582344 PMCID: PMC7306232 DOI: 10.4103/jrms.JRMS_743_19
Source DB: PubMed Journal: J Res Med Sci ISSN: 1735-1995 Impact factor: 1.852
Akaike information criterion and Bayesian information criterion values for parametric models
| Distribution | AIC | BIC |
|---|---|---|
| Exponential | 1460.79 | 1501.20 |
| Weibull | 1460.05 | 1505.52 |
| Log logistic | 1454.37 | 1499.83 |
| Log-normal | 1441.47 | 1486.93 |
AIC=Akaike information criterion; BIC=Bayesian information criterion
Figure 1Probability plots for breast cancer data
Figure 2Cumulative hazard of patients with breast cancer by sex (a), no significant difference between males and females: P =0.505), by age (b), significant difference between higher and lower age: P =0.021), by morphology (c), significant difference among morphology types: P <0.001) and by grade (d), significant difference among different grades: P <0.001)
Parameter estimates and 95% confidence interval for log-normal accelerated failure time model
| Variable | Exponential | Weibull | Log logistic | Log normal | ||||
|---|---|---|---|---|---|---|---|---|
| Time ratio (95% CI) | Time ratio (95% CI) | Time ratio (95% CI) | Time ratio (95% CI) | |||||
| Age | ||||||||
| <50 | Reference | Reference | Reference | Reference | ||||
| ≥50 | 0.72 (0.55-0.95) | 0.019* | 0.74 (0.58-0.95) | 0.018* | 0.72 (0.56-0.93) | 0.012* | 0.69 (0.53-0.90) | 0.007* |
| Sex | ||||||||
| Female | Reference | Reference | Reference | Reference | ||||
| Male | 0.81 (0.36-1.84) | 0.617 | 0.83 (0.40-1.75) | 0.635 | 0.80 (0.35-1.82) | 0.590 | 0.71 (0.30-1.69) | 0.439 |
| Grade | ||||||||
| I | Reference | Reference | Reference | Reference | ||||
| II | 0.65 (0.42-1.01) | 0.057 | 0.67 (0.45-0.99) | 0.047* | 0.65 (0.44-0.97) | 0.035* | 0.64 (0.43-0.96) | 0.031* |
| III | 0.49 (0.31-0.76) | 0.002* | 0.53 (0.35-0.80) | 0.003* | 0.49 (0.32-0.74) | 0.001* | 0.44 (0.28-0.67) | <0.001* |
| IV | 0.38 (0.22-0.66) | 0.001* | 0.42 (0.25-0.69) | 0.001* | 0.38 (0.23-0.66) | <0.001* | 0.35 (0.20-0.61) | <0.001* |
| Morphology | ||||||||
| DC | Reference | Reference | Reference | Reference | ||||
| LC | 1.72 (0.89-3.34) | 0.106 | 1.63 (0.89-2.97) | 0.114 | 1.76 (0.96-3.25) | 0.068 | 1.97 (1.05-3.72) | 0.035* |
| Other | 0.65 (0.43-0.98) | 0.039* | 0.66 (0.45-0.96) | 0.029* | 0.65 (0.43-0.97) | 0.038* | 0.61 (0.40-0.95) | 0.030* |
*P<0.05. CI=Confidence interval; DC=Ductal carcinoma; LC=Lobular carcinoma
Parameter estimates and 95% confidence interval for log-normal accelerated failure time model in women
| Variable | Time ratio (95% CI) | |
|---|---|---|
| Age | ||
| <50 | Reference | |
| ≥50 | 0.67 (0.51-0.88) | 0.004* |
| Grade | ||
| I | Reference | |
| II | 0.60 (0.40-0.91) | 0.017* |
| III | 0.40 (0.26-0.62) | <0.001* |
| IV | 0.32 (0.18-0.56) | <0.001* |
| Morphology | ||
| DC | Reference | |
| LC | 2.32 (1.20-4.48) | 0.012* |
| Other | 0.65 (0.42-1.02) | 0.060* |
*P<0.05. CI=Confidence interval; DC=Ductal carcinoma; LC=Lobular carcinoma